Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 25 Mar 2026 for Pyxis Oncology, Inc., €1,201. Read the official filing
Filing timeline
BuySaleRachel Humphrey
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Rachel Humphrey: trading record in brief
Rachel Humphrey is a declared insider of Pyxis Oncology, Inc. (senior executive), with filings sourced from SEC (Form 4). We count 3 filings; the first trade dates from 24 March 2023 and the latest from 14 April 2025.
The open-market record consists of 1 sale worth €1,201, with no purchase. The rest of the record consists of 2 share grants. 2026 to date brings no purchases and 1 sale.
The record was last updated on 25 March 2026 with an open-market sale (€1,201) in Pyxis Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Rachel Humphrey
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
1,400 shares@ US$0.97270.0008% mcap50.0% of flowCommon StockSEC:0000905148-26-001434:0
38,741 shares0Common StockSEC:0000950170-24-038099:0
58,064 shares0Common StockSEC:0001209191-23-021408:0
3 of 3 declarations
